Galectin Therapeutics Inc.
GALTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Galectin Therapeutics Inc. (GALT) is listed under Biotechnology. Valued at $417.5M, GALT is a small-cap name in its sector. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Market Cap
$417.5M
Beta
0.39
P/E (TTM)
—
P/E (Fwd)
-2.46
EPS (TTM)
$-0.43
EPS (Fwd)
$-1.68
ROE
—
ROA
-64.2%
Cash
$13.3M
Total Debt
$144.0M
Free CF
-$14.9M
52W Change
-6.9%
Annual Financials
Cash vs Debt
Where GALT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, GALT finished 46.41% above its 150-day moving average ($3.06) and 29.48% above its 200-day moving average ($3.46). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GALT overbought or oversold?
At the September 3, 2026 close, GALT's RSI(14) was 77.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $13.3M in cash, though total debt stands at $144.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$14.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
GALT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Galectin Therapeutics Inc. and its sector.